Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.
The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents.
Call your doctor for medical advice about side effects. Therefore, the efficacy of paroxetine extended-release tablets in combination with systemic including oral hormonal contraceptives for the continuous daily treatment of PMDD is unknown. Physicians should also note the results of a prospective longitudinal study of pregnant women with a history of major depression, who were either on antidepressants or had received antidepressants less than 12 weeks prior to their last menstrual period, and were in remission.
What are the ingredients in paroxetine extended-release tablets, USP? Only those events not previously listed for extended-release paroxetine are included.
T max was observed typically between 6 and 10 hours post-dose, reflecting a reduction in absorption rate compared with immediate-release formulations. Dose changes should occur at intervals of at least 1 week. Concomitant use of paroxetine extended-release tablets with other drugs metabolized by cytochrome CYP2D6 has not been formally studied but may require lower doses than usually prescribed for either paroxetine extended-release tablets or the other drug.
However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. Dosage Information in more detail.
If you have narrow-angle glaucoma, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Patients randomized to paroxetine were significantly less likely to relapse than comparably treated patients who were randomized to placebo. Stopping paroxetine extended-release tablets too quickly may cause serious symptoms including: In particular, some evidence suggests that SSRIs can cause such untoward sexual experiences.
Also tell them about any supplements you take.
Seek emergency medical attention or call the Poison Help line at Paroxetine extended-release tablets should be used cautiously in patients with a history of seizures. Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. The effectiveness of paroxetine extended-release tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials.
Although paroxetine is not known to cause drowsiness, it is advisable to avoid driving or operating hazardous machinery until you determine how paroxetine affects your ability to do these things safely. You should be closely monitored by your doctor for emotional and behaviour changes while taking this medication.
Anyone who develops seizures should seek immediate medical attention. Paroxetine extended-release tablets may be associated with these serious side effects: Abnormal ejaculation, somnolence, impotence, libido decreased, tremor, sweating, and female genital disorders generally anorgasmia or difficulty achieving orgasm. Events meeting the above criteria included the following: The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady-state.
The use of this medication by children and adolescents less than 18 years old may cause behavioural and emotional changes, such as suicidal thoughts and behaviour.